(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 November 2014 (06.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/178018 A1

(51) International Patent Classification:
C07K 14/575 (2006.01) *A61K 38/22* (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/IB2014/061123

(22) International Filing Date:
30 April 2014 (30.04.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/818,624 2 May 2013 (02.05.2013) US

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors: **DOCK, Steven Thomas**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **CARPENTER, Andrew James**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **HUNTER, III, Robert Neil**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **WU, Yulin**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US). **SRIVASTAVA, Ved P.**; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, Research Triangle Park, North Carolina 27709 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

[Continued on next page]

(54) **Title**: THERAPEUTIC PEPTIDES




FIG. 1

(57) **Abstract**: The present Invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs useful in the treatment of obesity, diabetes, and other disorders.

WO 2014/178018 A1

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*